{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:11:45Z","timestamp":1788880305619,"version":"build-2803163510"},"reference-count":36,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2730069","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:45:09Z","timestamp":1788878709000},"page":"2295-2309","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of elranatamab versus physician\u2019s choice of treatment (non\u2013BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7231","authenticated-orcid":false,"given":"Akira","family":"Yuasa","sequence":"first","affiliation":[{"name":"Japan Access & Value, Pfizer Japan Inc","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nagano","sequence":"additional","affiliation":[{"name":"Japan Access & Value, Pfizer Japan Inc","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kamei","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan G.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Hatsuyama","sequence":"additional","affiliation":[{"name":"Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"HTA, Value & Evidence, Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"HTA, Value & Evidence, Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Myeloma\/AL Amyloid Unit, Japanese Red Cross Medical Center","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04045-6"},{"issue":"6","key":"e_1_3_8_3_1","first-page":"35","article-title":"Real-world data analysis in Japanese patients with multiple myeloma in the novel drug era in Japan","volume":"15","author":"Murakami H","year":"2025","unstructured":"Murakami H, Abe M, Nio M, et al. Real-world data analysis in Japanese patients with multiple myeloma in the novel drug era in Japan. Int J Myeloma. 2025;15(6):35\u201343.","journal-title":"Int J Myeloma"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02404-6"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_8_10_1","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson LD","year":"2021","unstructured":"Anderson LD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021;39:8016.","journal-title":"J Clin Oncol"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024582"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188591"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.005"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_8_15_1","unstructured":"Ministry of Health Labour and Welfare. The 2024 abridged life table 2024 Japanese. [cited 2025 Dec 1]. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/life24\/houkokusho.html."},{"key":"e_1_3_8_16_1","unstructured":"National Institute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. TA658 2020 [cited 2025 Dec 1]. https:\/\/www.nice.org.uk\/guidance\/ta658."},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2277850"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049"},{"key":"e_1_3_8_19_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Summary of cost-effectiveness evaluation of elranatamab (Elrexfio); 2025 [cited 2025 Dec 1]. https:\/\/c2h.niph.go.jp\/results\/C2H2403\/C2H2403_Summary_Eng.pdf"},{"key":"e_1_3_8_20_1","volume-title":"An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody [DOF]","author":"Pfizer Inc","year":"2024","unstructured":"Pfizer Inc. An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody [DOF]. New York: Pfizer Inc; 2024."},{"key":"e_1_3_8_21_1","volume-title":"Internal documents","author":"Pfizer Inc","year":"2023","unstructured":"Pfizer Inc. Internal documents. New York: Pfizer Inc; 2023."},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.1834"},{"key":"e_1_3_8_23_1","unstructured":"Ministry of Health Labour and Welfare. Medical service fees in Japan; 2025 [cited 2025 Dec 1]. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryouhoken\/newpage_21053.html"},{"key":"e_1_3_8_24_1","unstructured":"Ministry of Health Labour and Welfare. Various information of medical fee; 2024. [cited 2025 Dec 1]. https:\/\/shinryohoshu.mhlw.go.jp\/"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2020.0649"},{"key":"e_1_3_8_26_1","unstructured":"Janssen Pharmaceutical KK. Tecvayli (teclistamab [genetical recombination]) injection; 2025 [cited 2025 Dec 1]. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00071603.pdf."},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000721"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00748-5"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00333-7"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S501404"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2026.2686032"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03535-9"},{"key":"e_1_3_8_33_1","unstructured":"National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma: TA510; 2018 [cited 2025 Dec 1]. https:\/\/www.nice.org.uk\/guidance\/ta510"},{"key":"e_1_3_8_34_1","unstructured":"National Institute for Health and Care Excellence. Ixazomib citrate for treating relapsed or refractory multiple myeloma: TA505; 2016 [cited 2025 Dec 1]. https:\/\/www.nice.org.uk\/guidance\/ta505"},{"key":"e_1_3_8_35_1","unstructured":"National Institute for Health and Care Excellence. Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma after at least two regimens including lenalidomide and bortezomib: TA427; 2016 [cited 2025 Dec 1]. https:\/\/www.nice.org.uk\/guidance\/ta427"},{"key":"e_1_3_8_36_1","unstructured":"National Institute for Health and Care Excellence. Panobinostat for treating multiple myeloma after at least 2 previous treatments: TA380; 2016 [cited 2025 Dec 1]. https:\/\/www.nice.org.uk\/guidance\/ta380."},{"key":"e_1_3_8_37_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council (\u201c2026 edition\u201d); 2026 [cited 2026 Aug 19]. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en_2026.pdf"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2730069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2730069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2730069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:45:13Z","timestamp":1788878713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2730069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2730069"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2730069","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}